Khanani, MD, MA, FASRS, Director of Clinic Research at Sierra Eye Associates ... Ocular's product candidate for retinal disease, is based on its ELUTYX proprietary bioresorbable hydrogel-based ...
PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces it has submitted a ...